Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

As a matter of scientific fact: Applying the inherency doctrine in biotechnology

Prior art that seems to only vaguely resemble your invention may later serve to invalidate your patent if appropriate steps are not taken early on.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. See Lindenmann Maschinenfabrik GmbH v. American Hoist and Derrick Co., 730 F.2d 1452, 1458 (Fed. Cir. 1984).

  2. See Corning Glass Works v. Sumitomo Elec. USA Inc., 868 F.2d 1251, 1255-56 (Fed. Cir. 1989) (citing Kalman v. Kimberly-Clark Corp., 713 F.2d 760, 771 (Fed. Cir. 1983)).

  3. Continental Can Co. USA v. Monsanto Co., 948 F.2d 1264,1268-69 (Fed. Cir. 1991).

  4. Id. (quoting In re Oelrich, 666 F.2d 578,581 (C.C.P.A. 1981)(quoting Hansgirg v. Kemmer, 102 F.2d 212, 214 (C.C.P.A. 1939)).

  5. 877 F. Supp. 531 (D. Col. 1994).

  6. Id. at 536-37.

  7. Id. at 1583.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moroz, E., Schildkraut, M. As a matter of scientific fact: Applying the inherency doctrine in biotechnology. Nat Biotechnol 15, 1403–1404 (1997). https://doi.org/10.1038/nbt1297-1403

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1297-1403

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing